Demographic, clinical characteristics and immunomodulatory treatments of 575 patients according to H1N1 vaccine group
| All patients (N=575) | Adjuvanted vaccines (N=499) | Non-adjuvanted vaccine (N=76) | p Value† | |
| Demographic characteristics | ||||
| Sex | 0.331 | |||
| Male, n (%) | 263 (46.1) | 224 (45.3) | 39 (51.3) | |
| Age (years), mean (SD) | 40.3 (14.0) | 40.4 (14.1) | 40.1 (13.1) | 0.892 |
| Pregnancy, n (%) | 6 (1.0) | 6 (1.2) | 0 (0) | 1 |
| Clinical characteristics | ||||
| IBD phenotype* | ||||
| CD, n (%) | 407 (70.8) | 348 (69.7) | 59 (77.6) | |
| UC, n (%) | 159 (27.6) | 142 (28.5) | 17 (22.4) | 0.242 |
| IC, n (%) | 9 (1.6) | 9 (1.8) | 0 (0) | |
| Disease duration (years), median (IQR) | 8 (4;15) | 8 (4;15) | 9.5 (4;16) | 0.576 |
| Age of diagnosis | ||||
| A1 | 53 (13.2) | 46 (13.3) | 7 (12.0) | |
| A2 | 277 (69.1) | 241 (69.4) | 36 (66.7) | 0.858 |
| A3 | 71 (17.7) | 60 (17.3) | 11 (20.3) | |
| Disease location | ||||
| L1 | 118 (30.0) | 101 (29.4) | 17 (33.3) | |
| L2 | 99 (25.2) | 84 (24.5) | 15 (29.4) | 0.404 |
| L3 | 176 (44.8) | 158 (46.1) | 18 (35.3) | |
| L4 | 22 (5.5) | 16 (4.7) | 6 (11.1) | 0.099 |
| Disease behaviour | ||||
| B1 | 180 (48.0) | 152 (47.5) | 28 (50.9) | |
| B2 | 107 (28.5) | 91 (28.4) | 16 (29.1) | 0.798 |
| B3 | 88 (23.5) | 77 (24.1) | 11 (20.0) | |
| p+ | 102 (25.6) | 95 (27.5) | 7 (13.0) | 0.022 |
| Extent of UC | ||||
| E1 | 15 (10.1) | 13 (9.7) | 2 (13.3) | |
| E2 | 53 (35.6) | 48 (35.8) | 5 (33.3) | 0.903 |
| E3 | 81 (54.3) | 73 (54.5) | 8 (53.4) | |
| Immunomodulatory treatments | ||||
| Corticosteroids, n (%) | 65 (11.3) | 52 (10.4) | 13 (17.1) | 0.086 |
| Azathioprine/6MP, n (%) | 319 (55.5) | 274 (54.9) | 45 (59.2) | 0.482 |
| Methotrexate, n (%) | 39 (6.8) | 36 (7.2) | 3 (3.9) | 0.289 |
| Anti-TNF therapies, n (%) | 280 (48.7) | 251 (50.3) | 29 (38.2) | 0.048 |
| Infliximab, n (%) | 171 (29.7) | 157 (31.5) | 14 (18.4) | 0.02 |
| Adalimumab, n (%) | 98 (17) | 84 (16.8) | 14 (18.4) | 0.732 |
| Certolizumab, n (%) | 11 (1.9) | 9 (1.8) | 2 (2.6) | 0.646 |
| Calcineurin inhibitors, n (%) | 3 (0.5) | 3 (0.6) | 0 (0) | 1 |
| Others, n (%) | 13 (2.3) | 8 (1.6) | 5 (6.6) | 0.019 |
| Monotherapy, n (%) | 240 (41.7) | 205 (41.1) | 35 (46.1) | 0.413 |
| Receipt of additional vaccines | ||||
| H1N1 booster (2nd injection), n (%) | 212 (36.9) | 140 (28.1) | 72 (94.7) | 0.001 |
| Seasonal influenza vaccine, n (%) | 328 (57) | 291 (58.3) | 37 (48.7) | 0.114 |
| Pneumococcal vaccine, n (%) | 70 (12.2) | 68 (13.6) | 2 (2.6) | 0.006 |
Adjuvanted vaccines are Pandemrix, Focetria and FluvalP. Non-adjuvanted vaccine is Celvapan.
↵* According to Montreal classification.
↵† Depicts difference between adjuvanted vaccines and non-adjuvanted vaccine.
CD, Crohn's disease; IBD, inflammatory bowel disease; IC, indeterminate colitis; TNF, tumour necrosis factor; UC, ulcerative colitis; 6-MP, 6 mercaptopurine.